BOSSI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 404
EU - Europa 198
AS - Asia 78
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
Totale 685
Nazione #
US - Stati Uniti d'America 403
IT - Italia 77
IE - Irlanda 42
DE - Germania 36
CN - Cina 23
SG - Singapore 19
HK - Hong Kong 16
RU - Federazione Russa 15
SE - Svezia 15
TR - Turchia 8
IN - India 7
ID - Indonesia 5
FI - Finlandia 4
GB - Regno Unito 4
EU - Europa 3
DK - Danimarca 2
FR - Francia 2
CA - Canada 1
CO - Colombia 1
PE - Perù 1
UA - Ucraina 1
Totale 685
Città #
Ann Arbor 211
Dublin 42
Milan 29
Frankfurt am Main 27
Wilmington 27
Chandler 23
New York 22
Hong Kong 16
Singapore 13
Fairfield 12
Shanghai 11
Ashburn 8
Cambridge 8
Seattle 8
Woodbridge 8
Houston 7
Princeton 6
Fremont 5
Jakarta 5
Kocaeli 5
Santa Clara 5
Duncan 4
Helsinki 4
Rome 4
Ankara 3
Bologna 3
Colorado Springs 3
Lawrence 3
Abbiategrasso 2
Aurora 2
Beijing 2
Bonndorf 2
Brugherio 2
Carugate 2
Fisciano 2
Guangzhou 2
Hebei 2
Lissone 2
Los Angeles 2
Monmouth Junction 2
Nanjing 2
Altamura 1
Andover 1
Austin 1
Boardman 1
Bogotá 1
Carate Brianza 1
Desio 1
Falls Church 1
Grafing 1
Hounslow 1
Hyderabad 1
Ivrea 1
Jacksonville 1
Jinan 1
Leawood 1
London 1
Monza 1
Mountain View 1
Munich 1
Nanchang 1
Pune 1
Redmond 1
Rocca Canavese 1
San Diego 1
Southwark 1
Stockholm 1
Toronto 1
Treviso 1
Turin 1
Totale 577
Nome #
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 255
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 173
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 122
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 51
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 43
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 39
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 38
Totale 721
Categoria #
all - tutte 2.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.675


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202077 0 0 0 0 0 9 16 7 9 21 9 6
2020/2021263 9 2 22 35 26 37 28 25 19 18 25 17
2021/202262 14 14 11 3 1 5 2 2 1 1 3 5
2022/2023101 6 27 10 3 11 12 4 2 5 1 10 10
2023/2024186 5 8 20 9 30 45 30 2 19 2 2 14
2024/202532 10 22 0 0 0 0 0 0 0 0 0 0
Totale 721